SCHEMBL7515779

SCHEMBL7515779

CC(C(=O)O)N1CC[C@@]2(CCCN2C(=O)OCC2c3ccccc3-c3ccccc32)C1=O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP5 Q01469 3/20 0.35
FABP7 O15540 2/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
EPHX2 P34913 1/20 0.34
MDM4 O15151 1/20 0.34
TP53 P04637 1/20 0.34
KMT2A Q03164 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
CASP3 P42574 1/20 0.34
FDFT1 P37268 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7515772 1.00 FABP5 (0.35) FABP5FABP7MMP1MMP2MMP9
SCHEMBL9740757 0.89 EPHX2 (0.34) FABP5FABP7MMP1MMP2MMP9
SCHEMBL14265225 0.83 KMT2A (0.38) FABP5FABP7EPHX2KMT2ATSHR
SCHEMBL7525979 0.83 MMP2 (0.43) MMP2MMP9
SCHEMBL7525973 0.83 MMP2 (0.43) MMP2MMP9
SCHEMBL7525987 0.83 MMP2 (0.43) MMP2MMP9
SCHEMBL14282653 0.82 KMT2A (0.38) FABP5FABP7EPHX2KMT2ATSHR
SCHEMBL9740759 0.80 KMT2A (0.37) FABP5FABP7EPHX2MDM4TP53
SCHEMBL7618670 0.75 MMP2 (0.44) MMP2MMP9
SCHEMBL18154894 0.75 EPHX2 (0.43) FABP5FABP7EPHX2KMT2ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020187934-A1 Peptide derivatives SYNGENTA LIMITED (GB) 2002-12-12 US disclosed
US-20020103335-A1 PEPTIDE DERIVATIVES ASTRAZENECA UK LIMITED (GB) 2002-08-01 US disclosed
US-6087336-A ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS ZENECA LIMITED (GB) 2000-07-11 US disclosed
EP-0914333-A1 PEPTIDE DERIVATIVES ZENECA LIMITED (GB) 1999-05-12 EP disclosed
WO-1997046578-A1 PEPTIDE DERIVATIVES ZENECA LIMITED (GB) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103335-A1 PEPTIDE DERIVATIVES HLA-DRB1, MICA, TAP1 FABP5 453/4885FABP7 2084/4885MMP1 2211/4885
US-20020187934-A1 Peptide derivatives HLA-DRB1, MICA, TAP1 FABP5 2883/4885FABP7 4291/4885MMP1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.